Chinanews.com, Hong Kong, November 24 (Reporter Wang Jiacheng) The Chief Executive of the Hong Kong Stock Exchange, Ou Guansheng, said at the Asian Healthcare Summit on the 24th that the biotechnology ecosystem in the Hong Kong stock market is becoming more and more prosperous, with more and more overseas biotechnology companies. Inquire about listing in Hong Kong.
He introduced that since the IPO reform in 2018, 79 healthcare companies have been listed in Hong Kong, raising more than 200 billion Hong Kong dollars.
Healthcare companies are one of the main industries for the potential supply of Hong Kong stock IPOs (initial public offerings). There are currently 55 such companies applying for listing, which shows the rapid growth of the industry.
The Hong Kong Stock Exchange will launch new financial products, such as exchange-traded funds (ETF), in response to changes in the ecosystem.
Ou Guansheng also said that many of the listed biopharmaceutical companies are unprofitable companies. The financial industry provides financing channels for this industry, which is a good example of the financial industry's contribution to the real economy.
(over)